CNBC Anchors and Reporters
Meg Tirrell
Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
More
- By: Melissa Lee
CNBC's Meg Tirrell reports on Comcast to give its employees a $1,000 bonus on the passage of the tax bill.
CNBC's Meg Tirrell reports on Wells Fargo announcing they will raise their minimum wage and donate $400 million after the passage of tax reform.
CNBC's Meg Tirrell reports on the quarterly earnings report for Bed, Bath, and Beyond.
CNBC's Meg Tirrell reports on Fifth Third Bank giving a raise and a one-time bonus to its workers because of the tax reform bill passage.
Akili, a Boston-based tech company, hopes to one day have doctors prescribe their video games to help treat cognitive and neurological conditions, CNBC’s Meg Tirrell reports.
CNBC's Meg Tirrell reports on Teva announcing cutting 14,000 jobs as the company aims to save $3 billion.
CNBC's Meg Tirrell reports the latest on announced layoffs at Teva Pharmaceuticals
- By: Landon Dowdy
U.S. stock futures were higher on Thursday morning after the Federal Reserve hiked interest rates during its December policy meeting this week.
- By: Melissa Lee
CNBC's Meg Tirrell speaks with Hans Bishop, Juno Therapeutics CEO, to discuss the company's down day and progress on its cancer treatment.
CNBC's Meg Tirrell speaks with Agios CEO David Schenkein about how the company is zeroing in on cancerous and noncancerous blood diseases.
